ChromaDex Corp. (CDXC) - Pangali EV/EBITDA

This daily price chart for ChromaDex Corporation (CDXC) demonstrates an EV/EBITDA of . ChromaDex Corporation (CDXC) relies on a staff of biochemists developing anti-aging nutraceuticals. Management's strategy is based on the global promotion of longevity through licensing and direct sales. Business scalability is driven by the wholesale distribution of patented components, which reduces costs and enhances operational efficiency within the health food sector.

Objective portfolio management requires comparing the enterprise value, including net debt, against operating profit before taxes and amortization. This indicator reveals the gap between the market price and the actual efficiency of assets by excluding the impact of the debt load. By analyzing the current EV/EBITDA trend of ChromaDex Corporation (CDXC), an investor can assess the resilience of ChromaDex Corporation (CDXC) amidst fierce competition in the lightly regulated dietary supplement market.